ULCID 20 Milligram Capsules Gastro-Resistant Ireland - English - HPRA (Health Products Regulatory Authority)

ulcid 20 milligram capsules gastro-resistant

astellas pharma co. ltd - omeprazole - capsules gastro-resistant - 20 milligram

Vesitirim 5 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

vesitirim 5 mg film-coated tablets

astellas pharma co. limited - solifenacin succinate - film-coated tablet - 5 milligram(s) - drugs for urinary frequency and incontinence; solifenacin

Vesitirim 10 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

vesitirim 10 mg film-coated tablets

astellas pharma co. limited - solifenacin succinate - film-coated tablet - 10 milligram(s) - drugs for urinary frequency and incontinence; solifenacin

Prograf 0.5mg hard capsules Malta - English - Medicines Authority

prograf 0.5mg hard capsules

astellas pharma europe b.v. - tacrolimus - hard capsule - tacrolimus milligram(s) - immunosuppressants

Prograf 1mg hard capsules Malta - English - Medicines Authority

prograf 1mg hard capsules

astellas pharma europe b.v. - tacrolimus - hard capsule - tacrolimus 1 milligram(s) - immunosuppressants

Prograf 5mg hard capsules Malta - English - Medicines Authority

prograf 5mg hard capsules

astellas pharma europe b.v. - tacrolimus - hard capsule - tacrolimus 5 milligram(s) - immunosuppressants

Prograf 5mg/ml concentrate for solution for infusion Malta - English - Medicines Authority

prograf 5mg/ml concentrate for solution for infusion

astellas pharma europe b.v. - tacrolimus - concentrate for solution for infusion - tacrolimus 5 milligram(s)/millilitre - immunosuppressants

Xtandi European Union - English - EMA (European Medicines Agency)

xtandi

astellas pharma europe b.v. - enzalutamide - prostatic neoplasms - endocrine therapy - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5.1).the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5.1).the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1).the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.